Table S1. Experimental pIC50 values for the chalcones used for the QSAR study
Table S2. Pharmacokinetics parameters for C8 and BZ
Figure S1. Correlation between Goldscore values and IC50 values against cruzain
Figure S2. 1H NMR spectrum (200 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-phenylprop-2-en-1-one (C1)Figure S3. 13C NMR spectrum (50 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-phenylprop-2-en-1-one (C1)Figure S4. 1H NMR spectrum (200 MHz, CDCl3) of (E)-1,3-bis(5-chlorothiophen-2-yl)prop-2-en-1-one (C2)Figure S5. 13C NMR spectrum (50 MHz, CDCl3) of (E)-1,3-bis(5-chlorothiophen-2-yl)prop-2-en-1-one (C2)Figure S6. 1H NMR spectrum (200 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (C3)
Figure S7. 13C NMR spectrum (50 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (C3)
Figure S8. 1H NMR spectrum (200 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(4-methylphenyl)prop-2-en-1-one (C4)Figure S9. 13C NMR spectrum (50 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(4-methylphenyl)prop-2-en-1-one (C4)Figure S10. 1H NMR spectrum (200 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(3-nitrophenyl)prop-2-en-1-one (C5Figure S11. 13C NMR spectrum (50 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(3-nitrophenyl)prop-2-en-1-one (C5)Figure S12. 1H NMR spectrum (200 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (C6)Figure S13. 13C NMR spectrum (50 MHz, CDCl3) of (E)-3-(5-chlorothiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (C6)Figure S14. 1H NMR spectrum (200 MHz, CDCl3) of (E)-1-(4-bromophenyl)-3-(5-chlorothiophen-2-yl)prop-2-en-1-one (C7)Figure S15. 13C NMR spectrum (50 MHz, CDCl3) of (E)-1-(4-bromophenyl)-3-(5-chlorothiophen-2-yl)prop-2-en-1-one (C7)Figure S16.